Imunogenicidade e reatogenicidade da vacina contra hepatite B derivada de Hansenula polymorpha comparada a Saccharomyces cerevisiae em homens privados de liberdade

• Autor(a) principal: Sandim, Lucíola Silva
• Data de Publicação: 2019
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UFG
• dARK ID: ark:/38995/001300000b26f
• Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tede/9691
• topic: Vacina contra hepatite B; Imunogenicidade; Privados de liberdade; Hepatitis B vaccine; Immunogenicity; Prisoners; CIENCIAS DA SAUDE::ENFERMAGEM

Hepatitis B virus infection still poses a serious threat to global health, since there is no "virological cure" and vaccination, considered the main pillar of eradication of the disease, did not reach the coverage rates recommended. The objective of this study was to evaluate the response of the hepatitis B vaccine to men deprived of their liberty from a prison in the state of Goiás, Central Brazil, comparing a vaccine with Hansenula polymorpha expression system to Saccharomyces cerevisiae. The participants were divided into two groups - Group 1 (SERUM - Hansenula polymorpha) and Group 2 (EUVAX - Saccharomyces cerevisiae). Vaccines were administered at months 0, 1 and 6. The Geometric Mean (MGT) of anti- HBs after the third dose of the vaccine was 656.1 (95% CI: 446.6, 972.7) of G1 and 203.7 (95% CI: 69.3, 597.0) of G2. Unadjusted analysis showed that G1 MGT was statistically higher than that observed in G2 (p-value = 0.075). The seroconversion rate (anti-HBs titers> 10 mIU / mL) was 100% for G1 and 82.8% for G2, with a trend toward higher seroconversion in G1 than G2 (p-value = 0.058). HIV infection (RTIaj 3.76, p-value = 0.035) and obesity (RTIaj 4.95, p-value = 0.017) were associated with inadequate vaccine response. Regarding reatogenicity, there was no statistical difference between groups (p-value = 0.501). Evidence from this investigation shows that the two vaccines, with different expression systems, were satisfactory in this clinical trial, although all nonresponders belonged to group 2 with Saccharomyces cerevisiae expression system. It is believed to be important to continue monitoring the performance of these vaccines in adults with a view to improving their immunogenicity, by assessing the factors that interfere with the vaccine response.